KLRD1 and ovarian serous adenocarcinoma: <h4>Introduction</h4>Combination approaches are being explored to improve immunotherapy efficacy, yet the immunomodulatory effects of chemotherapy on NK cell receptors and their ligands remain unexplored in high-grade serous ovarian cancer (HGSOC).